New Journey(SZ:002219) Guohai Securities·2025-09-09 06:33Investment Rating - The report maintains a "Buy" rating for the company [1][8]. Core Views - The impact of medical insurance and centralized procurement policies is stabilizing, and the company's performance is expected to improve in the second half of 2025 [2][5]. - The company reported a revenue of 1.588 billion yuan in the first half of 2025, a decrease of 20.63% year-on-year, with a net profit of 7 million yuan, down 88.25% [5]. - The company's hospital outpatient volume and average outpatient fees remained stable year-on-year, while inpatient volume decreased by approximately 9% [5][6]. - The company is expected to see improved growth rates in the second half of 2025 due to lower revenue baselines from key hospitals in 2024 [5][8]. - The company is enhancing its market share and operational efficiency through strategic restructuring and expansion [5][8]. Financial Summary - The company’s projected revenues for 2025-2027 are 3.474 billion yuan, 3.911 billion yuan, and 4.471 billion yuan, with year-on-year growth rates of -9%, +13%, and +14% respectively [7][8]. - The projected net profits for the same period are 92 million yuan, 117 million yuan, and 180 million yuan, with growth rates of -20%, +28%, and +53% respectively [7][8]. - The company’s price-to-earnings (P/E) ratios are projected to be 80.43, 62.92, and 41.07 for 2025, 2026, and 2027 respectively [7][8].